{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-090086","form_type":"8-K","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2026-08-04T12:05:12+00:00","discovered_at":"2026-08-04T12:10:00.369635+00:00","generated_at":"2026-08-04T12:10:27.641529+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Harmony Biosciences Q2 revenue $261.3M (+30% YoY); EPS $1.28; reiterates FY guidance $1.0-1.04B","bullets":["Q2 net revenue $261.3M, up 30% YoY; average patients 8,950 (+450).","Net income $75.4M ($1.28 diluted EPS) vs $39.8M ($0.68) in Q2 2025.","Reiterates 2026 WAKIX net revenue guidance of $1.0B-$1.04B.","BP-205 Phase 1 SAD data favorable; Phase 1b in sleep-deprived volunteers starts Q3; Phase 2 mid-2027.","Cash and investments $962.5M as of June 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-090086","json":"https://secwatch.observer/filing/0001104659-26-090086.json","markdown":"https://secwatch.observer/filing/0001104659-26-090086.md","text":"https://secwatch.observer/filing/0001104659-26-090086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/0001104659-26-090086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000110465926090086/hrmy-20260804x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-04T12:10:27.641529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}